Inclusion Criteria

- Patients must have received prior treatment which included both an anthracycline
(i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).

- Patients must have received no more than two prior chemotherapy regimens. Patients
who have not received treatment for metastatic disease must have relapsed within one
year.

- Patients may not have any history of brain and/or leptomeningeal metastases.

- Patients may not have Grade 2 or worse neuropathy at the time of study entry.

- Patients may not have had prior treatment with any epothilones and/or capecitabine
(i.e. Xeloda)